Similar articles

• Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.

  Teebken OE, Strüber M, Harringer W, Pichlmaier MA, Haverich A. Teebken OE, et al. Transplant Proc. 2002 Jun;34(4):1265-8. doi: 10.1016/s0041-1345(02)02640-4. Transplant Proc. 2002. PMID: 12072335 Clinical Trial. No abstract available.
• Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine.

  Sgrosso JL, Ferrer J, Araujo G, Romeo L, Parisi C, Vázquez MC. Sgrosso JL, et al. Transplant Proc. 2002 Feb;34(1):115-6. doi: 10.1016/s0041-1345(01)02695-1. Transplant Proc. 2002. PMID: 11959214 No abstract available.
• Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy.

  Sánchez V, Delgado JF, Blasco T, Dalmau R, Morales JM, Escribano P, Tello R, Hernández J, Velázquez T, Sotelo T, Gómez-Sánchez MA, Sáenz de la Calzada C. Sánchez V, et al. Transplant Proc. 1999 Sep;31(6):2515-6. doi: 10.1016/s0041-1345(99)00442-x. Transplant Proc. 1999. PMID: 10500695 No abstract available.
• New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.

  Hunt SA. Hunt SA. Cardiol Rev. 2000 May-Jun;8(3):180-4. Cardiol Rev. 2000. PMID: 11174892 Review.
• Review of major clinical trials with mycophenolate mofetil in cardiac transplantation.

  Kobashigawa JA, Meiser BM. Kobashigawa JA, et al. Transplantation. 2005 Oct 15;80(2 Suppl):S235-43. doi: 10.1097/01.tp.0000186383.22264.b3. Transplantation. 2005. PMID: 16251856 Review.